This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zheng, J. Articles by Clevenger, C. V. Search for Related Content PubMed PubMed Citation Articles by Zheng, J. Articles by Clevenger, C. V.

Prolyl Isomerase Cyclophilin A Regulation of Janus-Activated Kinase 2 and the Progression of Human Breast Cancer

Breast Cancer Program, Robert H. Lurie Comprehensive Cancer Center and Department of Pathology, Northwestern University, Chicago, Illinois

Requests for reprints: Charles V. Clevenger, Department of Pathology, Northwestern University, Lurie 4-107, 303 East Superior Street, Chicago, IL 60611. Phone: 312-503-5750; Fax: 312-503-0095; E-mail: clevenger{at}northwestern.edu.

Key Words: cyclophilin A • cyclosporine A • Jak2 • peptidyl-prolyl isomerase • prolactin receptor • growth hormone receptor

The activation of the Janus-activated kinase 2 (Jak2) tyrosine kinase following ligand binding has remained incompletely characterized at the mechanistic level. We report that the peptidyl-prolyl isomerase (PPI) cyclophilin A (CypA), which is implicated in the regulation of protein conformation, is necessary for the prolactin (PRL)-induced activation of Jak2 and the progression of human breast cancer. A direct correlation was observed between the levels or activity of CypA and the extent of PRL-induced signaling and gene expression. Loss of PRLr-CypA binding, following treatment with the PPI inhibitor cyclosporine A (CsA), or overexpression of a dominant-negative PRLr mutant (P334A) resulted in a loss of PRLr/Jak2–mediated signaling. In vitro, CsA treatment of breast cancer cells inhibited their growth, motility, invasion, and soft agar colony formation. In vivo, CsA treatment of nude mice xenografted with breast cancer cells induced tumor necrosis and completely inhibited metastasis. These studies reveal that a CypA-mediated conformational change within the PRLr/Jak2 complex is required for PRL-induced transduction and function and indicate that the inhibition of prolyl isomerases may be a novel therapeutic strategy in the treatment of human breast cancer. [Cancer Res 2008;68(19):7769–78]

This article has been cited by other articles:

				C. Desmetz, C. Bascoul-Mollevi, P. Rochaix, P.-J. Lamy, A. Kramar, P. Rouanet, T. Maudelonde, A. Mange, and J. Solassol Identification of a New Panel of Serum Autoantibodies Associated with the Presence of In situ Carcinoma of the Breast in Younger Women Clin. Cancer Res., July 15, 2009; 15(14): 4733 - 4741. [Abstract] [Full Text] [PDF]

				F. Fang, A. J. Flegler, P. Du, S. Lin, and C. V. Clevenger Expression of Cyclophilin B is Associated with Malignant Progression and Regulation of Genes Implicated in the Pathogenesis of Breast Cancer Am. J. Pathol., January 1, 2009; 174(1): 297 - 308. [Abstract] [Full Text] [PDF]